EC approves extension of indication for Janssen-Cilag's Darzalex
The European Commission (EC) has approved the extension of indication for Janssen-Cilag International's Darzalex (daratumumab) subcutaneous (SC) formulation to be used in the frontline setting for treating newly diagnosed multiple myeloma (NDMM) in adults.
Janssen-Cilag is a Johnson & Johnson (J&J) company.
The approval allows for the use of daratumumab SC in conjunction with bortezomib, lenalidomide and dexamethasone (daratumumab-VRd).
The therapy currently holds nine indications approved for multiple myeloma (MM) with five for frontline treatment, including regimens for patients both eligible and ineligible for autologous stem-cell transplant (ASCT).
The latest approval follows October 2024's indication extension for daratumumab-VRd to treat newly diagnosed patients eligible for ASCT, supported by the Phase III PERSEUS trial results.
The trial focused on assessing the therapy's SC-based quadruplet regimen for consolidation and induction therapy with daratumumab SC and lenalidomide maintenance.
The trial assessed the safety and efficacy of daratumumab-VRd against VRd in NDMM subjects who were either transplant ineligible or for whom ASCT was not intended as initial treatment.
Daratumumab-VRd's overall safety profile was consistent with the known profiles of daratumumab SC and VRd.
Johnson & Johnson innovative medicine EMEA therapeutic area haematology lead Edmond Chan stated: 'Daratumumab has become a cornerstone of multiple myeloma treatment over the past decade and is now the only anti-cluster of differentiation 38 (CD38) antibody approved to treat all patient types in the frontline setting, regardless of transplant eligibility.
'This latest approval confirms the enhanced benefit of daratumumab SC-based quadruplet regimens and its versatility and effectiveness in addressing the diverse needs of those affected by this complex disease.'
J&J also filed a supplemental biologics licence application with the US Food and Drug Administration in September 2024 for a new indication for daratumumab SC with VRd to treat adults with NDMM who are either ineligible for ASCT or for whom ASCT is deferred.
In 2024, the company announced the submission of a type II variation application to the European Medicines Agency (EMA) for its Darzalex-based quadruplet therapy for MM.
In 2012, J&J's Janssen Biotech and Genmab entered a global agreement granting J&J exclusive development, manufacturing and commercialisation rights for daratumumab.
"EC approves extension of indication for Janssen-Cilag's Darzalex" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
- A refreshed global brand signals JCR's expanded international presence and unwavering focus on rare and genetic diseases worldwide - HYOGO, Japan, June 06, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. "At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world," said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. "In September, we celebrate the 50th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases." The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: View source version on Contacts Investors & Media:JCR Pharmaceuticals Co., Communicationsir-info@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
a day ago
- Business Wire
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR'), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. 'At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'In September, we celebrate the 50 th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases.' The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo ® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo ® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO ® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website:
Newsweek
2 days ago
- Newsweek
Could Elon Musk Be Deported By Donald Trump? What to Know
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Steve Bannon has called for Elon Musk to be deported from the United States, after the dramatic bust up between the tech billionaire and President Donald Trump. In his War Room podcast Thursday, Trump's former White House chief strategist from his first term said: "Elon Musk is illegal … Deport immediately." The validity of Bannon's claim about Musk's naturalized U.S. citizen status is now likely to face more scrutiny than ever. Newsweek contacted Musk for comment on Friday via emails sent to the press offices of Tesla and SpaceX, where he serves as CEO, outside of regular office hours. Why It Matters Over the past few months Musk had been one of Trump's closest political allies spending $292 million to support him and other Republicans during the 2024 presidential election, providing vocal support on his social media platform X and heading the newly created Department of Government Efficiency (DOGE) which he left at the end of May. However, in the past week this relationship unraveled and Musk has now suggested Trump should be impeached and replaced by Vice President JD Vance, while the president suggested Musk's companies could lose government contracts potentially imperiling SpaceX's relationship with NASA. What To Know Speaking to the New York Times on Thursday, prominent conservative commentator Bannon said: "They should initiate a formal investigation of his immigration status because I am of the strong belief that he is an illegal alien, and he should be deported from the country immediately." Bannon later doubled down on this argument during an appearance on his War Room podcast when he said: "Elon Musk is illegal, and he's got to go. He's illegal? Deport immediately." "You're going to ship these other people home. Let's start with the South Africans, OK?" In October, 2024, the Washington Post published an article claiming that Musk had previously "worked illegally in the United States" by setting up a company while on a student visa in 1995, despite never enrolling in Stanford University as promised. Citing "former business associates, court records and company documents" the publication said Musk used a J-1 student visa to enter the U.S. but instead worked on a startup that became Zip2 without the requisite work visa. According to the Post, in a 2005 email used in a defamation lawsuit, Musk admitted that he applied to Stanford because he otherwise had "no legal right to stay in the country." President Donald Trump speaking at a roundtable in the State Dining Room at the White House on June 05, 2025 in Washington, D.C. (left) and Elon Musk addressing reporters in the Oval Office of the... President Donald Trump speaking at a roundtable in the State Dining Room at the White House on June 05, 2025 in Washington, D.C. (left) and Elon Musk addressing reporters in the Oval Office of the White House on May 30, 2025 in Washington, D.C. (right). More Anna Moneymaker/Kevin Dietsch/GETTY The case was raised at a campaign event by then President Joe Biden who said: "That wealthiest man in the world turned out to be [an] illegal worker here when he was here. "I'm serious. He was supposed to be in school when he came on a student visa. He wasn't in school. He was violating the law. He's talking about all these illegals coming our way?" In a post on X shortly after the Post's story was published Musk denied the allegation against him, saying: "I was in fact allowed to work in the U.S." Born in Pretoria, South Africa, in 1971, Musk moved to Canada in 1989 and later to the United States in 1992 to attend the University of Pennsylvania. He became a U.S. citizen in 2002 through the naturalization process after several years of living and working in the country. U.S. law states that citizenship gained through naturalization can be revoked if it was "procured by concealment of a material fact or by willful misrepresentation." Speaking to Wired about Musk, Professor Stephen Yale-Loehr, an immigration law expert at Cornell Law School, said that if the claims of illegal working are true "on purely legal grounds, this would justify revoking citizenship, because if he had told the truth, he would not have been eligible for an H1-B, a green card, or naturalization." Amanda Frost, a legal expert at the University of Virginia, said: "If a noncitizen violated the terms of a nonimmigrant visa, and then adjusted to immigrant (green card) status without admitting the violation, and then naturalized without admitting the violation, that person could be denaturalized on the ground that their naturalization was 'illegally procured." In a string of attacks on Friday, Musk called for Trump to be impeached, described what the president called his "Big Beautiful [spending] Bill" as "The Big Ugly Bill" and said Trump's tariffs policy would cause a recession in the second half of 2025. Trump fired back on his Truth Social website claiming Musk "just went CRAZY" adding: "The easiest way to save money in our Budget, Billions and Billions of Dollars, is to terminate Elon's Governmental Subsidies and Contracts. I was always surprised that Biden didn't do it!" As the row intensified Musk posted: "Time to drop the really big bomb: @realDonaldTrump is in the Epstein files. That is the real reason they have not been made public." What People Are Saying In a post on X, conservative commentator Charlie Kirk said: "Let me get this straight: Democrats tried to put Trump in prison for 700 years, take his business empire from him, impeach him twice, take him off the ballot, and censor him on all social media—all the while they were sitting on info that Trump was on the Epstein list? This is total and complete nonsense." Reacting to the Trump-Musk bust up House Democrat Alexandria Ocasio-Cortez said: "Oh man the girls are fighting aren't they?" On X, Ashley St. Clair, the mother of one of Musk's children, posted: "hey @realDonaldTrump lmk [let me know] if u need any breakup advice." What's Next It remains to be seen whether the Trump-Musk feud will continue and if so to what extent it will influence government policy. Trump has not given any indication he think's Musk's American citizenship should be investigated and according to Politico the two men are due to speak on Friday.
